Marvel Health Files for IPO Following Major Strategic Contract with Listed Chinese Company, Pioneering Global Oral Anti-Aging Market with Synthetic Biology

As the 4th Global Digital Trade Expo drew to a close, Marvel Health, an Australian anti-aging enterprise specializing in globalized synthetic biology, announced a major strategic partnership with the corporate group of Sunwave Communications (Stock Code: 002115), a company listed on China’s A-share market. The agreement was signed through Fuxing International Capital, Sunwave Communications’ Hong Kong-based capital platform, with comprehensive omnichannel operational support provided by its core subsidiary, Juwang Technology, a leading service provider on Douyin E-commerce. This collaboration has injected strong momentum into Marvel Health’s ongoing new round of financing.

This Australian-origin enterprise has built a “scientific evidence + full industry chain” model, leveraging its practical experience in successfully transforming from beauty devices to oral anti-aging products, thereby providing a proven, comprehensive pathway for similar companies undergoing cross-industry transformation.

The 4th Global Digital Trade Expo brought together exhibitors from 154 countries and regions, with the proportion of international exhibitors exceeding 20%. At this grand event themed around technology trade, a large number of professional buyers gathered at the booth of Australia’s Manwei.

Australian Manwei at the 4th Global Digital Trade Expo

Ying Xinxiang, Strategic Partner of Manwei Australia, stated: “What was pleasantly surprising is that over 60% of the clients who inquired at the exhibition had backgrounds in medicine or biology. They are no longer satisfied with marketing rhetoric; instead, they paid particular attention to our NAD+ intervention mechanisms and the principles of mitochondrial repair.””

The Australian Manwei booth attracted South African clients and Russia’s largest e-commerce platform,

Singapore’s Cross-Border Health Supplement Platform and Other Professional Clients from Around the World

This level of professional market attention reflects the anti-aging industry’s transition from concept-driven marketing to science-led development. During the exhibition, AusManwei and Fuxing International Capital successfully signed a major strategic cooperation agreement, demonstrating the market’s genuine demand for technology-based anti-aging products.

Regarding this collaboration, Chen Li, founder of Australian Manwei, stated: “Prior to finalizing this partnership, both parties engaged in six months of communication and mutual understanding. Juwang Technology has affirmed Australian Manwei’s technology and products, its business development model, and the niche sector in which it operates.””

“The fundamental difference between us and traditional health supplement companies is that we have established a complete chain of scientific evidence, from basic research to industrialization.””Ying Xinxiang explained. Ausmanvi’s R&D system is built upon three major technological breakthroughs:

1. Mechanism Innovation: In-depth Exploration of NAD+ Pathways for Aging Intervention

The company focuses on research into NAD+ biosynthesis and mitochondrial function repair, discovering that elevating intracellular NAD+ levels through precursor substances can activate the sirtuin family of longevity proteins and improve mitochondrial function. This research is protected by 12 PCT international patents.

2. Technological Breakthrough: Synthetic Biology Enables High-Efficiency Production

Through in-depth collaboration with leading synthetic biology companies such as Shenghe Wanwu and Meiliu Bio, we have jointly developed high-yield engineered strains, boosting the synthesis efficiency of NAD+ precursors by 300%. Ying Xinxiang stated, “We have established a comprehensive synthetic biology industry alliance, possessing full-chain capabilities ranging from gene sequence design to large-scale production.””

3. Validation Innovation: Organ-on-a-Chip Replaces Animal Testing

Establishment of an Efficacy Validation Platform for Organ-on-a-Chip: Utilizing NAD+ Bioluminescent Probe Technology (with a sensitivity of 0.1 μmol/L), this platform not only shortens the efficacy validation cycle by 70% but also enables real-time monitoring of NAD+ level changes at the cellular level, while complying with international ethical standards.

Australia's Manwei has built a complete industrial ecosystem through strategic partnerships:

Collaborating with Shenghe Wanwu:Jointly develop ergothioneine biosynthesis technology, break through the industry bottlenecks of low yield and high cost associated with chemical synthesis, and achieve large-scale production.

Alliance with Meiliu Bio:Co-develop an innovative raw material R&D platform, focus on the biosynthesis of natural products, and develop multiple novel active ingredients with independent intellectual property rights.

Collaborative Innovation:By integrating cutting-edge global vitamin technologies with NAD+ intervention mechanisms, the company has developed a synergistic anti-aging regimen tailored for specific populations, dedicated to delivering more targeted, personalized nutritional support.

Ying Xinxiang told VCBeat, “These collaborations have not only strengthened our R&D capabilities; more importantly, Australia’s Manwei has built a comprehensive industrial ecosystem that provides partners with end-to-end solutions from raw materials to finished products.””

Manwei Australia’s global brand practices have validated its “raw materials – certification – production – brand””Full end-to-end operational capability. The following cases not only demonstrate its own commercial achievements but also paint a clear picture of collaboration for potential partners:

Mode 1: Cross-Border Raw Material Rebirth Solution

Taking GABA as an example, leveraging Australia’s mature and robust regulatory environment, AusManwei can complete the approval process for dietary supplements within 6–9 months. Currently, AusManwei has helped revalue multiple domestic raw materials; one medical aesthetics device brand utilized its TGA approval capabilities to transform an active ingredient into an oral anti-aging product within nine months, achieving first-month sales exceeding RMB 3 million.

Australia Manwei's Raw Material Export Strategy

Mode 2: Technology Sharing and Collaborative Development

Manwei Australia shares synthetic biology technologies with its partners to co-develop new products. Taking Manwei’s Ergothioneine Anti-Aging and Skin-Brightening Ultra-Light Capsules as an example, this product employs a “mitochondrial energy–collagen metabolism–pigment regulation”Three-tier synergistic mechanism: experimental data show that skin firmness increases by 98% and under-eye wrinkles are reduced by approximately 90% after several weeks of use.

 Successfully launched by Australian Manwei based on the collaborative development model,

Ergothioneine Anti-Aging and Whitening Super Light Capsules Offer Significant Efficacy Advantages

Model 3: Full-Chain Empowerment Case Services

Leveraging mature operational models on e-commerce platforms such as Douyin and Tmall, Ausmanwei provides end-to-end services ranging from product registration to marketing and promotion. Chen Li revealed, “Ausmanwei’s Ximeiba product has achieved an overall repurchase rate exceeding 68%, significantly surpassing the industry average of 40%. On the first day of the 2025 Tmall Global ‘Double 11’ shopping festival, Ximeiba topped the sales charts for intestinal-cleansing fruit and vegetable dietary fiber, as well as leading both the repurchase and positive review rankings.””

Australian Manwei Prune Product: Comprehensive Intestinal-Cleansing Fruit, Vegetable, and Dietary Fiber Formula

“No. 1 on the Sales, Repurchase, and Positive Review Charts”

All products are manufactured in cleanroom facilities dual-certified by the TGA and the FDA, adhering to pharmaceutical-grade GMP standards. From raw material screening to final product release, each item undergoes inspection at 217 quality control points. These rigorous standards enable Manwei products to be suitable for special populations, including infants and pregnant women.

Furthermore, the Australian Manwei production system has obtained certification from Australia’s Therapeutic Goods Administration (TGA) and U.S. FDA GRAS status, and its products are trusted by top-tier sports organizations such as Borussia Dortmund Football Club and the Chinese National Diving Team.

 Australian Manwei enjoys high visibility among government officials and business elites.

The core value of Ausvine’s latest partnership lies in its strategic endorsement by Juwang Technology, a leading industry service provider. This is far more than a simple business collaboration; its deeper significance is that Juwang Technology’s rigorous product selection process (with an acceptance rate of less than 3%) serves as an authoritative “market stress test.” Its endorsement provides the most efficient validation of Ausvine’s product strength, business model, and growth potential. For companies seeking financing, such recognition from a key link in the industrial chain carries far greater persuasive power than the company’s own marketing efforts, significantly boosting investor confidence and valuation expectations in the capital markets.

As a leading service provider that has consistently ranked among the top three in Douyin E-commerce’s third-party operations sector for three consecutive years (data source: 2024 “Report on the Comprehensive Strength of Chinese Internet Enterprises”), Junetech’s industry recognition carries triple strategic value:

Market Validation Benchmark:The collaboration itself serves as the ultimate validation of Australia’s Manwei product system—passing Juwang Technology’s rigorous selection process (with an acceptance rate of less than 3%) and being included in its annual core client list is equivalent to obtaining a “inspection-free certification” in the field of internet marketing.

Growth Logic Made Concrete:Within Juwang Technology’s service matrix, clients in the same big health sector as Australia’s Manwei (such as Swisse and Move Free) have achieved an average annual GMV growth rate of over 150%, providing a direct benchmark for Manwei’s expansion into the North American market.

Capital Dialogue Bridge:Strategic partnerships with leading service providers can enhance the confidence level of financial institutions’ risk assessments, thereby enabling Ausmanvi’s valuation model to achieve a more favorable P/S (price-to-sales) multiple.

The profound value of this strategic breakthrough lies in the fact that, backed by an industry leader, Ausmanvi’s R&D capabilities, supply chain system, and global layout have acquired quantifiable value anchors. Compared to mere financial metrics, the growth certainty endorsed by top-tier market players represents the core logic most closely watched by capital markets during the Pre-IPO stage. It demonstrates the company’s ability to scale and replicate its success, which is precisely the source of excess returns sought by venture capital.

Building on this partnership, Aussie Manwei has officially embarked on its global expansion journey, adopting a phased target approach aligned with three development stages: validating the Douyin e-commerce model in the first year, expanding into the North American market in the second year, and completing deployment across major global markets in the third year.

Driven by strong business performance, Ausmanvi has officially launched its initial public offering (IPO) plan and a new round of financing to support corporate R&D, North American market channel development, and strategic M&A.

Over the next three years, Ausmanvi will focus on advancing three key areas: deepening clinical research on NAD+ precursor drugs, expanding the application of organ-on-a-chip technology in efficacy validation, and developing personalized anti-aging solutions.

VCBeat Observation:Australian Manwei, by establishing an "industry-academia-research-application"”An integrated innovation system, forming strategic synergies with leading enterprises in the industrial chain. The success paradigm of Australian Manwei demonstrates that a company mastering core technologies is fully capable of bridging the entire value chain from raw materials to global branding, and providing ecosystem partners with proven transformation pathways. Its established “scientific evidence + full industry chain”model, has not only secured significant collaborations involving substantial financial commitments but also demonstrated that the technological development logic of Australian Manwei has gained industry recognition. Against the backdrop of industrial upgrading, this “research-industry”a virtuous cycle that will drive the anti-aging industry toward a technology-driven transformation.